Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
2003 1
2004 1
2005 2
2006 1
2007 2
2009 1
2010 3
2011 2
2012 4
2013 4
2014 4
2015 11
2016 7
2017 6
2018 4
2019 9
2020 11
2021 15
2022 12
2023 13
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531].
Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Simonetti E, Santangelo F, Amato G, Covre A, Camerini R, Valente M, Mandalà M, Giannarelli D, Calabrò L, Maio M. Di Giacomo AM, et al. Eur J Cancer. 2024 May;202:113981. doi: 10.1016/j.ejca.2024.113981. Epub 2024 Mar 9. Eur J Cancer. 2024. PMID: 38461074 No abstract available.
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.
Lofiego MF, Piazzini F, Caruso FP, Marzani F, Solmonese L, Bello E, Celesti F, Costa MC, Noviello T, Mortarini R, Anichini A, Ceccarelli M, Coral S, Di Giacomo AM, Maio M, Covre A; EPigenetic Immune-oncology Consortium Airc (EPICA) investigators. Lofiego MF, et al. Among authors: di giacomo am. J Transl Med. 2024 Mar 1;22(1):223. doi: 10.1186/s12967-024-05040-x. J Transl Med. 2024. PMID: 38429759 Free PMC article.
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective.
Roccuzzo G, Gherardi E, Maio M, Malagoli P, Marzano AV, Parodi A, Pimpinelli N, Spagnolo F, Di Giacomo AM, Quaglino P. Roccuzzo G, et al. Among authors: di giacomo am. Expert Opin Biol Ther. 2024 Mar;24(3):125-131. doi: 10.1080/14712598.2024.2326168. Epub 2024 Mar 3. Expert Opin Biol Ther. 2024. PMID: 38421218 Review.
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Simonetti E, Santangelo F, Amato G, Covre A, Camerini R, Valente M, Mandalà M, Giannarelli D, Calabrò L, Maio M. Di Giacomo AM, et al. Eur J Cancer. 2024 Mar;199:113531. doi: 10.1016/j.ejca.2024.113531. Epub 2024 Jan 11. Eur J Cancer. 2024. PMID: 38271746 Free article. Clinical Trial.
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Mandalà M, Lorigan P, Sergi MC, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Tucci M, Guida M, Spagnolo F, Rossi E, Occelli M, Queirolo P, Quaglino P, Depenni R, Merelli B, Placzke J, Di Giacomo AM, Del Vecchio M, Indini A, da Silva IP, Menzies AM, Long GV, Robert C, Rutkowski P, Ascierto PA. Mandalà M, et al. Among authors: di giacomo am. Eur J Cancer. 2024 Mar;199:113542. doi: 10.1016/j.ejca.2024.113542. Epub 2024 Jan 19. Eur J Cancer. 2024. PMID: 38266540 Free article.
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream.
Calabrò L, Bronte G, Grosso F, Cerbone L, Delmonte A, Nicolini F, Mazza M, Di Giacomo AM, Covre A, Lofiego MF, Crinò L, Maio M. Calabrò L, et al. Among authors: di giacomo am. Front Immunol. 2024 Jan 8;14:1333661. doi: 10.3389/fimmu.2023.1333661. eCollection 2023. Front Immunol. 2024. PMID: 38259475 Free PMC article. Review.
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR, Di Giacomo AM, Caruso FP, Covre A, Mortarini R, Scala G, Costa MC, Coral S, Fridman WH, Sautès-Fridman C, Brich S, Pruneri G, Simonetti E, Lofiego MF, Tufano R, Bedognetti D, Anichini A, Maio M, Ceccarelli M. Noviello TMR, et al. Among authors: di giacomo am. Nat Commun. 2023 Sep 22;14(1):5914. doi: 10.1038/s41467-023-40994-4. Nat Commun. 2023. PMID: 37739939 Free PMC article. Clinical Trial.
112 results